Angiotensin-converting enzyme inhibitors - the risk of dementia and possibilities of improving cognitive functions:the unique characteristics of perindopril

Cover Page

Cite item

Full Text

Abstract

The article considers the possibility of 5 major classes of antihypertensive drugs to reduce the risk of dementia and to impact on cognitive functions. It is noted that angiotensin-converting enzyme inhibitors do not have a class effect associated with cerebral protection. We show in detail the results of perindopril usage for the prevention of dementia and improvement of cognitive functions. We discuss the mechanisms of cerebral protection in case of applying perindopril.

About the authors

O. D Ostroumova

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation; I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation

Email: ostroumova.olga@mail.ru
д-р мед. наук, проф. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова, проф. каф. клинической фармакологии и профболезней ГБОУ ВПО Первый МГМУ им. И.М.Сеченова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

N. Yu Galeeva

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation

соискатель каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

O. V Bondarets

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

T. F Guseva

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

I. I Kopchenov

A.I.Evdokimov Moscow State Medical and Dental University of the Ministry of Health of the Russian Federation

канд. мед. наук, доц. каф. факультетской терапии и профболезней ГБОУ ВПО МГМСУ им. А.И.Евдокимова 127473, Russian Federation, Moscow, ul. Delegatskaia, d. 20, str. 1

References

  1. Захаров В.В., Локшина А.Б. Когнитивные нарушения в общеклинической практике. М., 2009.
  2. Larrieu S, Letenneur L, Orgogozo J.M. Incidence and outcome of mild cognitive impairment in a population - based prospective cohort. Neurology 2002; 59: 1594-9.
  3. Левин О.С. Диагностика и лечение деменции в клинической практике. М.: МЕДпресс - информ, 2010.
  4. Диагностика и лечение артериальной гипертензии // Системные гипертензии. 2010; 6 (3): 5-26.
  5. Henderson A.S. Dementia. World Health Organization, Geneva, 1994.
  6. Amaducci L, Andrea L. The epidemiology of the dementia in Europe. In: A.Culebras, J.Matias Cuiu, G.Roman (eds): New concepts in vascular dementia. Barselona: Prous Science Publishers, 1993; p. 1927.
  7. Skoog I, Lernfelt B, Landahl S et al. 15-years longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-5.
  8. Launer L.J, Masaki K, Petrovitch H et al. The assotiation between midlife blood pressure levels and late - life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995; 274: 1846-51.
  9. Singh-Manoux A, Marmot M. High blood pressure was associated with cognitive function in middle - age in the Whitehall II study J. Clin Epidemiol 2005; 58: 1308-15.
  10. Forette F, Seux M-L, Staessen J.A et al. for the Syst-Eur Investigators. The Prevention of Dementia with Antihypertensive Treatment. New evidence from the Systolic Hypertension (Syst-Eur) Study. Arch Intern Med 2002; 162 (18): 2046-52.
  11. Lithell H, Hansson L, Skoog I et al; SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double - blind intervention trial. J Hypertens 2003; 21: 875-86.
  12. PROGRESS collaborative study group. Randomised trial of perindopril based blood pressure - lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-41.
  13. Marpillat N.L, Macquin-Mavier I, Tropeano A-I et al. Antihypertensive classes, cognitive decline andincidence of dementia: a networkmeta - analysis. J Hypertens 2013, 31 (6): 1073-82.
  14. Chiu W-C, Ho W-C, Lin M-H et al; Health Data Analysis in Taiwan (hDATa) Research Group. Angiotension receptor blockers reduce the risk of dementia. J Hypertens 2014, 32: 938-47.
  15. The Progress Collaborative Group. Еffects of blood pressure lowering with perindopril and indapamade therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Int Med 2003;163: 1069-75.
  16. Левин О.С., Дамулин И.В. Диффузные изменения белого вещества (лейкоареоз) и проблема сосудистой деменции. В кн.: Достижения в нейрогериатрии. Под ред. Н.Н.Яхно, И.В.Дамулина. Ч. 2. М., 1995; с. 189-231.
  17. Dufouil С, Chalmers J, Coskun O. Effects of blood pressure lowering on cerebral white matter hyperintensities in patients with stroke: the PROGRESS (Perindopril Protection Against Recurrent Stroke Study) Magnetic Resonance Imaging Substudy. Circulation 2005; 112 (1l): 1644-50.
  18. Остроумова О.Д., Десницкая И.В. Подходы к лечению артериальной гипертонии в условиях стационара: коррекция артериального давления и состояние когнитивных функций. // Системные гипертензии. 2005; 1 (2): 14-7.
  19. Морозова Т.Е., Гонтаренко С.В. Влияние антигипертензивных препаратов на состояние когнитивных функций у больных артериальной гипертензией I-II степени. Лечащий врач. 2014; 7: 15-9.
  20. Fogari R, Mugellini A, Zoppi A et al. Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur. J Clin Pharmacol 2004; 59: 863-8.
  21. Sink К.М, Leng Х, Williamson J et al. Angiotensin Converting Enzyme Inhibitors and Cognitive Decline in Older Adults with Hypertension: Results from the Cardiovascular Health Study. Arch Intern Med 2009; 169 (13): 1195-202.
  22. Ohrui T, Tomita N, Sato-Nakagawa T et al. Effects of brain - penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-5.
  23. Pihlaja R, Kauppinen R, Koistinaho J, Koistinaho M. Multiple cellular and molecular mechanisms are involved in human Ab clearance by transplanted adult astrocytes. Glia 2011; 59 (11): 1643-57.
  24. Kehoe P.G, Wilcock G.K. Is inhibition of the renin - angiotensin system a new treatment option for Alzheimer’s disease? Lancet Neurol 2007; 6 (4): 373-8.
  25. Phillips M.I, de Oliveira E.M. Brain renin angiotensin in disease. J Mol Med 2008; 86 (6): 715-22.
  26. Ciobica A, Bild W, Hritcu L, Haulica I. Brain renin - angiotensin system in cognitive function: pre - clinical findings and implications for prevention and treatment of dementia. Acta Neurol Belg 2009; 109 (3): 171-80.
  27. Savaskan E, Hock C, Olivieri G et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging 2001; 22 (4): 541-6.
  28. Ferrari R, Pasanisi G, Notasrstefano P et al. Specific properties and effect of perindopril in controlling the renin - angiotensin system. Am J Hypertens 2005; 18: 142-54.

Copyright (c) 2022 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies